# OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And Lipoprotein(a) Reduction to Prevent First Major Cardiovascular Events

Study · id `cardio:ct-nct07136012` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07136012](<https://clinicaltrials.gov/study/NCT07136012>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07136012

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 11000 participants.

## Technical summary

Registry record NCT07136012. Randomized; double masking; primary purpose treatment. Start 2025-08-22 (actual); primary completion 2031-10-20 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 11000 participants (planned count; ClinicalTrials.gov record NCT07136012, source copy `cardio:ctgov-nct07136012-2026-11-16`, retrieved 2026-11-18)
- Started: 2025-08-22 (actual) (ClinicalTrials.gov record NCT07136012, source copy `cardio:ctgov-nct07136012-2026-11-16`, retrieved 2026-11-18)
- Primary completion: 2031-10-20 (anticipated) (ClinicalTrials.gov record NCT07136012, source copy `cardio:ctgov-nct07136012-2026-11-16`, retrieved 2026-11-18)
- Completion: 2031-10-20 (anticipated) (ClinicalTrials.gov record NCT07136012, source copy `cardio:ctgov-nct07136012-2026-11-16`, retrieved 2026-11-18)
- Countries: United States; Australia; Canada; China (ClinicalTrials.gov record NCT07136012, source copy `cardio:ctgov-nct07136012-2026-11-16`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07136012-2026-11-16`, retrieved 2026-11-18)

## The registry's words

- Brief title: OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And Lipoprotein(a) Reduction to Prevent First Major Cardiovascular Events
- Condition: Cardiovascular Disease
- Intervention (Drug): Olpasiran
- Intervention (Drug): Placebo
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)

## Provenance

Content hash: cc64fc60f138f15d3885be401a8fcbb0595eaf7c6440335d78b096e920f492f0
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
